S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 325-332

  He, Zhijuan ^a   Gao, Jianhua ^a   Wang, Qi ^a   Liu, Min ^b   Li, Yixuan ^b   Li, Xin ^b   Tang, Hua ^b,c   Zheng, Jianhua ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c NONE   (China)

Author keywords

Drug resistance; Ovarian cancer; S100P

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALCIUM BINDING PROTEIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; S100 CALCIUM BINDING PROTEIN P; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN OVCAR3; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; EXPRESSION VECTOR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE TEST; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CELL PROLIFERATION; EPIRUBICIN; ETOPOSIDE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 48749097670     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000010     Document Type: Article

References (24)

1. Tang H, Liu YJ, Liu M and Li X: Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs 18: 633-639, 2007.
2. 2+ binding properties. Eur J Biochem 207: 541-547, 1992.
3. Emoto Y, Kobayashi R, Akatsuka H and Hidaka H: Purification and characterization of a new member of the S-100 protein family from human placenta. Biochem Biophys Res Commun 182: 1246-1253, 1992.
4. Sato N and Hitomi J: S100P expression in human esophageal epithelial cells: Human esophageal epithelial cells sequentially produce different S100 proteins in the process of differentiation. Anat Rec 267: 60-69, 2002.
5. Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, Yang X and Russo J: S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol 16: 231-240, 2000.
6. Bertram J, Palfner K, Hiddemann W and Kneba M: Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 9: 311-317, 1998.
7. Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, Goldberger N, Elkahloun AG, Willi N, Koivisto P, Ferhle W, Raffeld M, Sauter G and Kallioniemi OP: Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 62: 1256-1260, 2002.
8. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB and Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824, 2002.
9. Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M and Tanaka M: S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 12: 5411-5416, 2006.
10. Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D and Lee K: S100 proteins in the epidermis. J Invest Dermatol 123: 23-33, 2004.
11. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
12. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET and Namiki M: The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67: 955-967, 2007.
13. Schmidt WM, Kalipciyan M, Dornstauder E, Rizovski B, Steger GG, Sedivy R, Mueller MW and Mader RM: Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 112: 200-212, 2004.
14. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK and Park JG: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284, 2004.
15. Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005.
16. 2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell 14: 2372-2384, 2003.
17. Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR and Crnogorac-Jurcevic T: The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res 67: 8633-8642, 2007.
18. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB and Kavallaris M: Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study. Proteomics 6: 1681-1694, 2006.
19. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M and De Vore RF III: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14: 2054-2060, 1996.
20. Filipek A, Jastrzebska B, Nowotny M and Kuznicki J: CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J Biol Chem 277: 28848-28852, 2002.
21. Ning X, Sun S, Hong L, Liang J, Liu L, Han S, Liu Z, Shi Y, Li Y, Gong W, Zhang S, Chen Y, Guo X, Cheng Y, Wu K and Fan D: Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res 5: 1254-1262, 2007.
22. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC and Huang EH: RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 50: 1230-1240, 2007.
23. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005.
24. Arumugam T, Simeone PM, van Golen K and Logsdon CD: S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 11: 5356-5364, 2005.